PHASE II TRIAL TO INVESTIGATE EFFICACY AND SAFETY OF BENDAMUSTINE, DEXAMETHASONE AND THALIDOMIDE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA PATIENTS AFTER TREATMENT WITH LENALIDOMIDE AND BORTEZOMIB

被引：0
|
作者：
Mian, M.
Pescosta, N. [1 ]
Luminari, S. [2 ]
Badiali, S. [2 ]
Marcheselli, L. [2 ]
Patriarca, F. [3 ]
Zambello, R. [4 ]
Mondello, P. [5 ]
Pascarella, A. [6 ]
Pitini, V. [5 ]
Cortelazzo, S. [7 ]
机构：
[1] Hosp Bolzano, Bolzano, Italy
[2] Univ Modena & Reggio Emilia, Dept Hematol & Oncol, Modena, Italy
[3] Azienda Osped Univ, Udine, Italy
[4] Univ Padua, Sch Med, Padua, Italy
[5] Univ Messina, Messina, Italy
[6] Osped Angelo, Venice, Mestre, Italy
[7] Humanitas Gavazzeni Canc Ctr, Bergamo, Italy
来源：
HAEMATOLOGICA | 2014年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PB1648
引用
收藏
页码：637 / 637
页数：1
相关论文
共 50 条
  • [31] Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma
    M A Dimopoulos
    A S Swern
    J S Li
    M Hussein
    L Weiss
    Y Nagarwala
    R Baz
    Blood Cancer Journal, 2014, 4 : e257 - e257
  • [32] Bendamustine-bortezomib-dexamethasone in relapsed/refractory multiple myeloma.
    Cerchione, Claudio
    Nappi, Davide
    Cangini, Delia
    Ronconi, Sonia
    Ceccolini, Michela
    Musuraca, Gerardo
    Martinelli, Giovanni
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [33] Final Results of a Phase I/II Trial of the Combination of Concurrent Lenalidomide, Thalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Myeloma
    Shah, Jatin J.
    Orlowski, Robert Z.
    Thomas, Sheeba K.
    Alexanian, Raymond
    Wang, Michael
    Qazilbash, Muzaffar H.
    Popat, Uday R.
    Parmar, Simrit
    Shah, Nina
    Bashir, Qaiser
    Champlin, Richard E.
    Weber, Donna M.
    BLOOD, 2012, 120 (21)
  • [34] A Phase I Study of Bendamustine Combined with Lenalidomide and Dexamethasone in Patients with Refractory or Relapsed Multiple Myeloma.
    Lentzsch, Suzanne
    O'Sullivan, Amy
    Lalo, Silvana
    Kruppa, Carrie
    Gardner, Diane
    Kennedy, Ryan C.
    Burt, Steve
    Mapara, Markus Y.
    Redner, Robert
    Roodman, David
    Volkin, Robert L.
    Zonder, Jeffrey
    BLOOD, 2009, 114 (22) : 736 - 736
  • [35] Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma
    Berenson, James R.
    Yellin, Ori
    Bessudo, Alberto
    Boccia, Ralph V.
    Noga, Stephen J.
    Gravenor, Donald S.
    Patel-Donnelly, Dipti
    Siegel, Robert S.
    Kewalramani, Tarun
    Gorak, Edward J.
    Nassir, Youram
    Swift, Regina A.
    Mayo, Debra
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 160 (03) : 321 - 330
  • [36] Phase II study of thalidomide with dexamethasone for relapsed/refractory multiple myeloma
    Kinoshita, T
    Ohno, T
    Yuge, M
    Hiraga, J
    Matsushita, T
    Ando, S
    Naoe, T
    ANNALS OF ONCOLOGY, 2005, 16 : 206 - 206
  • [37] Safety and efficacy of daratumumab with lenalidomide and dexamethasone in relapsed or relapsed, refractory multiple myeloma.
    Plesner, Torben
    Arkenau, Hendrik-Tobias
    Lokhorst, Henk M.
    Gimsing, Peter
    Krejcik, Jakub
    Lemech, Charlotte Rose
    Minnema, Monique
    Lassen, Ulrik Niels
    Ahmadi, Tahamtan
    Yeh, Howard
    Guckert, Mary
    Brun, Nikolai C.
    Lisby, Steen
    Basse, Linda
    Palumbo, Antonio
    Richardson, Paul G.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [38] Phase II study of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with relapsed or relapsed and refractory multiple myeloma (MM)
    Anderson, K. C.
    Jagannath, S.
    Jakubowiak, A.
    Lonial, S.
    Raje, N.
    Schlossman, R.
    Munshi, N.
    Knight, R.
    Esseltine, D.
    Richardson, P. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [39] A phase one trial of carfilzomib, bendamustine, and dexamethasone in relapsed and/or refractory multiple myeloma
    Lee, Hans C.
    Feng, Lei
    Oriabure, Onyeka
    Graham, Vivian
    Chen, Wendy
    Badillo, Maria
    Lu, Rebecca
    Lee, Hun J.
    Jain, Preetesh
    Manasanch, Elisabet E.
    Orlowski, Robert Z.
    Wang, Michael L.
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (07) : E243 - E246
  • [40] Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety
    Sung Sook Lee
    Cheolwon Suh
    Bong-Seog Kim
    Jooseop Chung
    Young-Don Joo
    Hun-Mo Ryoo
    Young Rok Do
    Jong-Youl Jin
    Hye Jin Kang
    Gyeong-Won Lee
    Moon Hee Lee
    Hyeok Shim
    Kihyun Kim
    Sung-Soo Yoon
    Soo Mee Bang
    Ho Young Kim
    Je-Jung Lee
    Jinny Park
    Dong Soon Lee
    Jae-Hoon Lee
    Annals of Hematology, 2010, 89 : 905 - 912
12345